tetano
Editor, Senior Moderator
J Card Surg. 2011 May 9. doi: 10.1111/j.1540-8191.2011.01261.x. [Epub ahead of print]
Use of Extracorporeal Membrane Lung Assist Device (Novalung) in H1N1 Patients.
Johnson P, Fr?hlich S, Westbrook A.
Source
Department of Intensive Care Medicine, St James's Hospital, Dublin, Ireland Department of Critical Care, Mater Misericordiae University Hospital, Dublin, Ireland Department of Anaesthesia and Critical Care, Midlands Regional Hospital, Mullingar, Ireland.
Abstract
Abstract We present three patients with severe respiratory failure secondary to H1N1 influenza type A pneumonitis, in whom hypercapnia and respiratory acidosis were not controlled by the conventional mechanical lung ventilation or high-frequency oscillatory ventilation. Use of a pumpless arteriovenous extracorporeal carbon dioxide removal device (Novalung?, Inspiration Healthcare Ltd, Leicester, UK) resulted in reduced carbon dioxide levels, improved pH, and a reduction in inspiratory pressures, allowing for a less-harmful ventilator strategy. These cases demonstrate that the Novalung is a safe and effective device to use in patients with H1N1 pneumonitis refractory to the conventional therapy and may be an alternative to extracorporeal membrane oxygenation (ECMO) in selected cases. (J Card Surg 2011;**:***-***).
? 2011 Wiley Periodicals, Inc.
PMID:
21554392
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21554392
Use of Extracorporeal Membrane Lung Assist Device (Novalung) in H1N1 Patients.
Johnson P, Fr?hlich S, Westbrook A.
Source
Department of Intensive Care Medicine, St James's Hospital, Dublin, Ireland Department of Critical Care, Mater Misericordiae University Hospital, Dublin, Ireland Department of Anaesthesia and Critical Care, Midlands Regional Hospital, Mullingar, Ireland.
Abstract
Abstract We present three patients with severe respiratory failure secondary to H1N1 influenza type A pneumonitis, in whom hypercapnia and respiratory acidosis were not controlled by the conventional mechanical lung ventilation or high-frequency oscillatory ventilation. Use of a pumpless arteriovenous extracorporeal carbon dioxide removal device (Novalung?, Inspiration Healthcare Ltd, Leicester, UK) resulted in reduced carbon dioxide levels, improved pH, and a reduction in inspiratory pressures, allowing for a less-harmful ventilator strategy. These cases demonstrate that the Novalung is a safe and effective device to use in patients with H1N1 pneumonitis refractory to the conventional therapy and may be an alternative to extracorporeal membrane oxygenation (ECMO) in selected cases. (J Card Surg 2011;**:***-***).
? 2011 Wiley Periodicals, Inc.
PMID:
21554392
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21554392